1. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.146
Figure 3 Modelling the effects of increasing the number of age cohorts vaccinated against HPV16/18 on time to reduction in the prevalence of HPV infection
Figure 3 | Modelling the effects of increasing the number of age cohorts vaccinated against HPV16/18 on time to reduction in the prevalence of HPV infection. Baussano et al.131 assessed the effectiveness of HPV16/18 vaccination, in terms of prevention of cervical HPV16/18 infections, among women aged ≤35 years, with catch-up vaccination of women aged 17–24 years. Using a mathematical model of HPV16/18 transmission and information on vaccination coverage among 11-year-old girls in an Italian population (65% coverage), the data were calculated based on the assumption of 50% vaccination coverage within the catch-up cohorts. Data were modelled for catch-up vaccination of women in four age groups, comprising between two and eight 1-year birth cohorts. Catch-up vaccination of an age group that spanned eight consecutive 1-year birth cohorts, encompassing women aged 17–24 years, was estimated to move forward by 2 years the time at which 50% vaccine effectiveness against HPV16/18 infection would be reached in the population. Abbreviation: HPV16/18, human papillomavirus types 16 and 18. Figure adapted from Baussano, I. et al. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 (2014); © 2014 Baussano et al.; licensee BioMed Central Ltd, which was published under a Creative Commons Attribution License 2.0 Generic (CC BY 2.0;
Figure adapted from Baussano, I. et al. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 (2014);
© 2014 Baussano et al.; licensee BioMed Central Ltd, which was published under a Creative Commons Attribution
License 2.0 Generic (CC BY 2.0;
Bosch, F. X. et al. (2015) HPV-FASTER: broadening the scope for prevention of HPV-related cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc